ISRCTN61345286已完成不适用
Randomised study on haemoglobin response in iron-deficient anaemic patients with solid malignancies receiving epoetin alfa (rHuEPO) in combination with either oral or parental iron supplementation during treatment with non-platinum containing chemotherapy
Vrije University Medical Centre (VUMC) (The Netherlands)0 个研究点目标入组 34 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Confirmed diagnosis of a solid malignancy and planned to receive further non-platinum containing chemotherapy for at least 12 weeks
- •2. Haemoglobin (Hb) less than or equal to 7.5 mmol/L at any time during chemotherapy
- •3. Transferrin saturation (TSAT) less than 20% and/or serum ferritin less than 100 ng/ml
- •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- •5. Life expectancy at least 3 months
- •6. Aged between 18 - 75 years
- •7. Sex: male or female. Female subjects must be either postmenopausal (for at least for 1 year), sterilised or, if of childbearing potential, be practising an acceptable method of birth control.
- •8. Subjects must have read and signed the informed consent form
排除标准
- •1. Mean corpuscular volume (MCV) less than 80 fL and mean corpuscular haemoglobin count (MCHC) less than 195 mmol/L
- •2. MCV greater than 100 fL
- •3. Clinically significant chronic blood loss
- •4. Clinically significant disease/dysfunction of the pulmonary, cardiovascular, endocrine, neurological, gastrointestinal, or genitourinary systems not attributable to underlying malignancy or chemotherapy. This dysfunction is only an exclusion criteria if it causes an expected early withdrawal from the study.
- •5. Uncontrolled hypertension, defined as a diastolic blood pressure greater than 100 mmHg, despite antihypertensive medication
- •6. History of seizures
- •7. Known hypersensitivity to Epoetin alfa or one of its components
- •8. Administration of intravenous iron preparations within 3 months before study entry
- •9. Participation in any other clinical trial involving unlicensed medication or procedures
- •10. Androgen therapy within two months of study entry
研究者
相似试验
已完成
不适用
Randomized study on hemoglobin response in iron-deficient anemic patients with solid maglignancies receiving epoetin alfa (rHuEPO) in combination with either oral or parental iron supplementation during treatment with non-platinum containing chemotherapy.IJzerdeficiente anemische patiënten met solide tumorenNL-OMON26767VU medisch centrum34
已完成
不适用
An investigation of factors associated with iron deficiency in high school long-distance runnersormalJPRN-UMIN000047010Takasaki University of Health and Welfare20
招募中
4 期
INFERR - Iron Infusion in Haemodialysis Study: Effect of Intravenous Iron Polymaltose on survival and hospitalisation rates for Indigenous Patients with High Ferritin Levels on HaemodialysisKidney diseaseanaemiahigh ferritinlow transferrin saturationHaemodialysisBlood - AnaemiaRenal and Urogenital - Kidney diseaseInflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonLiver diseaseACTRN12620000705987Menzies School of Health Research576
已完成
不适用
IRON DEFICIENCY IN ORAL SUBMUCOUS FIBROSISCTRI/2011/12/002200peoples college of dental sciences and research center bhopal90
已完成
不适用
Randomised controlled study of iron supplementation to support the response to recombinant human erythropoietin for the treatment of chemotherapy-induced anaemiaChemotherapy induced anaemiaHaematological DisordersAnaemia in chronic diseases classified elsewhereISRCTN11830961Barts and the London NHS Trust (UK)80